Skip to main content
. Author manuscript; available in PMC: 2015 Jun 8.
Published in final edited form as: Int J Cardiovasc Imaging. 2011 Mar 11;27(2):271–287. doi: 10.1007/s10554-011-9796-3

Fig. 2.

Fig. 2

% neointimal hyperplasia evaluated by both OCT and IVUS: from ODESSA trial. OCT is more sensitive for small amounts of neointimal reaction observed in sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) compared to zotarolimus-eluting stents (ZES) and bare metal stents (BMS), although both modalities are similarly sensitive for high % of neointimal hyperplasia (figure is courtesy of Dr Guagliumi) [44]